Vuélvete ilimitado con Magzter GOLD

Vuélvete ilimitado con Magzter GOLD

Obtenga acceso ilimitado a más de 9000 revistas, periódicos e historias Premium por solo

$149.99
 
$74.99/Año

Intentar ORO - Gratis

A tariff pill: Why India, US and China hold the key to affordable medicines

The Business Guardian

|

July 18, 2025

Donald Trump is back on the campaign trail, promising to slash drug prices. "I will get drug prices way down," he declared this year.

- RAKESH K. CHITKARA

A tariff pill: Why India, US and China hold the key to affordable medicines

Few Americans would argue with the urgency of affordable medicine, especially as health-care costs continue to burden families and government programs alike.

Yet, in April, President Trump imposed a sweeping 10% tariff on all imports, including pharmaceuticals and medical supplies, under the International Emergency Economic Powers Act. Simultaneously, his administration launched a national security investigation under Section 232 that could impose tariffs of up to 25% on finished drug products and active pharmaceutical ingredients (APIs). Generics, the backbone of affordable American medicine, are squarely in the crosshairs of these trade policies.

At first glance, tariffs appear as a tough stance against foreign suppliers, a way to protect American jobs and industries. But the reality is far more complex and, frankly, dangerous. These tariffs threaten to destabilize a drug supply chain that millions of Americans rely on daily and leave the United States far more exposed to future shocks.

India plays an outsized role in America's generic drug supply. According to the U.S. Food and Drug Administration (FDA), Indian manufacturers supply roughly 40% of the generics consumed in the United States. From antibiotics to blood pressure medicines to cancer therapies, these affordable drugs keep health care accessible for millions of patients and help contain the enormous costs borne by Medicare and Medicaid.

But India's generic industry has a critical vulnerability: it remains heavily dependent on China for its raw ingredients. Approximately 70% of the active pharmaceutical ingredients (APIs)—the chemical building blocks of all medicines—used by Indian generic producers are imported from China, according to India's Ministry of Commerce. This dependency is a geopolitical and economic risk waiting to materialize.

MÁS HISTORIAS DE The Business Guardian

The Business Guardian

The Business Guardian

CII unveils policy roadmap to shape India's Media and Entertainment future by 2030

The Confederation of Indian Industry (CII) has unveiled a comprehensive policy roadmap to transform India's Media and Entertainment (M&E) sector into a globally competitive powerhouse by 2030. The announcement came at the 12th CII Big Picture Summit 2025 in Mumbai, where leaders from government, industry, and creative sectors gathered to discuss the future of India's creative economy.

time to read

1 mins

December 02, 2025

The Business Guardian

The Business Guardian

ZELENSKYY IN PARIS, MEETS MACRON TO SEEK SUPPORT OVER TRUMP’S PEACE PLAN

Ukrainian President Volodymyr Zelenskyy met with French President Emmanuel Macron on Monday at the Elysée presidential palace in Paris, part of a flurry of diplomatic activity aimed at brokering the terms for a potential ceasefire in the nearly four-year-old war in Ukraine.

time to read

2 mins

December 02, 2025

The Business Guardian

The Business Guardian

India puts data sovereignty and chip self- reliance at core of expanding space push

India is sharpening its focus on data sovereignty and semiconductor self-reliance as its space programme accelerates, former ISRO chairman and Space Commission member Kiran Kumar said on Monday.

time to read

2 mins

December 02, 2025

The Business Guardian

The Business Guardian

FM INTRODUCES TWO BILLS IN LOK SABHA

Minister Sitharaman introduced the Central Excise (Amendment) Bill, 2025, and Health Security se National Security Cess Bill, 2025, in Lok Sabha, soon after the Parliament convened after a brief adjournment till noon.

time to read

1 mins

December 02, 2025

The Business Guardian

The Business Guardian

GST collection in November inches up 0.7% to touch Rs 1.70 lakh crore

The Goods and Services Tax (GST) collections in November posted marginal monthly growth even as year-to-date performance remained robust.

time to read

1 mins

December 02, 2025

The Business Guardian

FROM MACAULAY TO BNS: HOW INDIA IS REWRITING ITS CRIMINAL RULEBOOK

Late in November 2025, Delhi police swept up a group of students protesting at India Gate - first charging them under routine public-order sections, then adding Bharatiya Nyaya Sanhita (BNS) Section 197 (imputations prejudicial to national integration).

time to read

10 mins

December 02, 2025

The Business Guardian

Zelenskyy says 'tough issues' still need to be resolved after Florida talks

Tough issues have yet to be resolved after U.S.-Ukrainian talks in Florida, President Volodymyr Zelenskiy said on Monday, as he and other Ukrainian officials toured Europe to rally allies and Donald Trump's envoy headed to Moscow to brief the Kremlin.

time to read

1 min

December 02, 2025

The Business Guardian

The Business Guardian

Rupee hits new low as depreciation continues

The downside in the Indian rupee, which has been steadily depreciating over the past months, is unlikely to abate soon as it hit yet another record low on Monday.

time to read

2 mins

December 02, 2025

The Business Guardian

TVS MOTOR COMPANY SALES GROWS 30%

TVS Motor Company recorded monthly sales of 519,508 units in November 2025 with a growth of 30% as against 401,250 units in November 2024.

time to read

1 mins

December 02, 2025

The Business Guardian

The Business Guardian

WHY INDIA NEEDS AN INDEPENDENT ONLINE CONTENT REGULATOR: A SUPREME COURT-DRIVEN RETHINK

The Supreme Court's recent observation urging the creation of an independent online content regulator marks a defining moment in India’s digital policy discourse.

time to read

4 mins

December 02, 2025

Listen

Translate

Share

-
+

Change font size